Germany Surpasses 200 Tonnes of Medical Cannabis
PRESS RELEASE
29. March 2026

Germany Surpasses 200 Tonnes of Medical Cannabis Imports in 2025

 
Picture: [128239749/123RF]
Langenfeld – Germany, 2026-03-29

Germany Surpasses 200 Tonnes of Medical Cannabis Imports in 2025

Germany imports more than 200 tonnes of medical cannabis for the first time

In 2025, Germany surpassed the threshold of 200 tonnes of imported cannabis for medical or medical-scientific purposes for the first time. Industry reporting based on newly published BfArM data puts the annual volume at 201,094 kg. In 2024, imports had amounted to 72,706 kg. [1]

Einfuhrstatistik von Cannabisblüten zu medizinischen und medizinisch-wissenschaftlichen Zwecken in 2024/2025, aufgeteilt in Quartale

(Source: BfArM)

The development highlights the continued momentum of the German market. According to the published evaluations, import volumes increased strongly over the course of the year and remained at a historically high level. Canada remained the most important supplier country, while Portugal and other international source markets further expanded their role in supplying the German market. [1]
This trend is also visible at the official level. BfArM continues to publish quarterly import statistics for 2024/2025 as well as country-of-origin overviews for cannabis imported into Germany for medical and medical-scientific purposes. Under the MedCanG framework, each import or export of medical cannabis requires a corresponding authorisation by BfArM in addition to the necessary permit under Section 4 MedCanG. [2]
For pharmacies, pharmaceutical wholesalers, manufacturers and international partners, this development points to one clear conclusion: reliable supply chains, regulatory certainty and high-quality pharmaceutical processes are becoming even more important in the German medical cannabis market. [1][2]

 

For more information, see the following Source:

[1] MMJDaily – “Germany’s medical cannabis imports cross 200 tons”. Reported the 2025 import volume at 201,094 kg and the 2024 comparison at 72,706 kg.

[2] BfArM – “Medizinalcannabisverkehr – Ein-/Ausfuhr”. How much cannabis is currently imported into Germany for medical and scientific purposes?

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG) and Cannabis products under the Medical Cannabis Act (MedCanG) for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle cannabis products according to § 4 of the Medical Cannabis Act (MedCanG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
Record import of medicinal cannabis
PRESS RELEASE
30. April 2024

Record amount of medicinal cannabis in 2023

Langenfeld – Germany, 2024-04-30

Germany Imports Record Quantity of Medicinal Cannabis in 2023

Germany has imported a record quantity of cannabis for medicinal and scientific purposes in the year 2023.

According to the latest data from the Federal Institute for Drugs and Medical Devices (BfArM), Germany imported a total of 31,398 kilograms (34.6 tons) of cannabis products in 2023. This marks an impressive increase of 26.2% compared to the 24,876 kilograms imported in the previous year.

The rising import quantity reflects the growing interest of both national and international companies in participating in the booming market for medicinal cannabis in Germany.

 

For more information, see the following Source: Mjbizdaily

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

 

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG) and Cannabis products under the Medical Cannabis Act (MedCanG) for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle cannabis products according to § 4 of the Medical Cannabis Act (MedCanG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
PRESS RELEASE
25. March 2024

Long Road to Legalization: Federal Council Finally Approves Cannabis Legislation

Berlin – Germany, 2024-03-22

Historic decision: The Cannabis Legalization Act was passed without a mediation committee

The German Federal Council (Bundesrat) approved the Cannabis Act in its session on March 22, 2024. Requests for convening the Mediation Committee did not receive a majority.


Legal possession and consumption of limited amounts
The law provides for a partial legalization of cannabis. It allows for the possession of up to 25 grams, up to 50 grams within one’s own four walls. Additionally, the cultivation of three cannabis plants in one’s own apartment becomes legal, with the harvested cannabis intended solely for personal use and not for distribution.


For more information, see the following Source: Federal Council – 1042nd meeting on 22.03.2024

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
PRESS RELEASE
24. February 2024

The Bundestag approves the Cannabis Act (CanG)

Berlin – Germany, 2024-02-23

Milestone in Cannabis Regulation: The Cannabis Act (CanG) has been approved

The Ampel Coalition fulfilled the promise from the November 2021 coalition agreement by passing the CanG in the Bundestag on February 23, 2024.

The bill was first discussed in the Bundestag in October of last year, and since then, several adjustments have been made to the original draft. The law, passed in the second and third readings, is set to come into effect on April 1, 2024. It will allow the use of cannabis either through personal cultivation or as part of membership in a cultivation association. The cultivation associations are expected to become active from July 1, 2024, onwards.

The changes introduced by the CanG are scheduled for initial evaluation in 2025, with further evaluations planned at specific intervals.

The passage of the CanG in the Bundestag on February 23, 2024, marks a significant milestone on the path to the legalization of cannabis in Germany. This step constitutes the first part of a two-pillar plan developed by the federal government for its legalization initiative. The second pillar of the plan will involve a temporary pilot project, establishing specialized cannabis stores for the controlled distribution of cannabis for recreational use.

However, the implementation of the legislative initiative may still face delays, depending on the further actions of the Bundesrat, which is expected to provide its position on the CanG on March 22, 2024. While the Bundesrat cannot prevent the passage of the law by the Bundestag, it may engage the mediation committee to review the law.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
PRESS RELEASE
17. August 2023

Federal cabinet approves cannabis law

Berlin – Germany, 2023-08-16

Progress in Cannabis Regulation: New Law (CanG) Charts the Course

A significant milestone has been achieved today in the realm of cannabis as the cabinet has approved the “Draft Law on the Controlled Use of Cannabis and Amendments to Other Regulations” (CanG). This groundbreaking draft, based on an innovative two-pillar approach, is set to reshape the industry fundamentally. The reformation aims to regulate cannabis use while ensuring the protection of children and adolescents.

The CanG law includes provisions allowing adult citizens to cultivate up to three cannabis plants for personal use. Additionally, the possession of up to 25 grams of cannabis is decriminalized. Simultaneously, an advertising and sponsorship ban on consumption cannabis and cultivation associations is introduced to bolster youth protection.

Federal Minister of Health, Prof. Karl Lauterbach, emphasized, “The Cannabis Law marks an urgently needed shift in drug policy. Our goal is to curb the black market and decrease consumption rates. Despite legalization, we remain aware that cannabis can be harmful, especially to developing brains. Hence, we are launching an awareness campaign today to educate young people about the risks.”

Federal Minister of Agriculture, Cem Özdemir, added, “This law strikes a balance between individual freedom and public welfare. It grants adults legal access to cannabis while strengthening youth protection. We create secure, controlled, and legal avenues for cannabis consumption, while focusing on prevention and health protection.”

Natural Pharma, known as one of the trailblazers in product quality and transparency within the cannabis industry, welcomes this progressive legislation and is prepared to embrace the ensuing opportunities and challenges. The company remains committed to providing high-quality and safe cannabis products, while upholding the highest standards of compliance and consumer protection.

Source: https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/bundeskabinett-beschliesst-cannabisgesetz-pm-16-08-23.html

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
PRESS RELEASE
3. August 2023

Natural Pharma: Services for German pharmacies

Langenfeld (rhld.) – Germany, 2023-08-03

Natural Pharma Offers Premium Services for German Pharmacies

Natural Pharma Resource (Natural Pharma) GmbH, is delighted to introduce its premium services specifically tailored for German pharmacies. With a strong focus on excellence, Natural Pharma aims to assist German pharmacies in establishing a robust and effective online presence.

As the cannabis industry continues to evolve, pharmacies play a crucial role in providing patients with access to high-quality cannabis products. However, many pharmacies encounter challenges in effectively showcasing their offerings online. Natural Pharma has recognized these needs and developed a range of exceptional services to address them.

Leveraging its extensive expertise in the distribution of cannabis products, Natural Pharma now extends its services to support pharmacies in creating secure and informative websites. Through IT services that encompass website design and development, Natural Pharma ensures that pharmacies can present their product availability clearly and attractively.

A standout feature of Natural Pharma’s premium service is the seamless integration of a dedicated availability table for cannabis flowers, extracts, and applications. This secure table is accessible through a password-protected area, enabling patients and treating physicians to log in securely using DocCheck credentials. This ensures accurate recording of the correct and available medication on the prescription.

Natural Pharma firmly believes that a robust online presence is essential for German pharmacies to expand their reach and attract international patients. With their premium service offerings, they aspire to be the preferred partner for German pharmacies seeking a comprehensive solution for their online needs.

German pharmacies and healthcare professionals interested in learning more about Natural Pharma’s premium services can reach out to them via email at apotheken@natpha.de or by phone, Monday to Friday, between 10:00 and 18:00.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
PRESS RELEASE
16. February 2023

Natural Pharma continues its successful start to the new year!

Langenfeld (rhld.) – Germany, 2023-02-16

Natural Pharma continues its successful start to the new year by expanding and deepening its partnerships to offer patients additional therapy options.

In January 2023, Natural Pharma successfully expanded its product range and now offers 400g bags of Bedrocan. The company is pleased to have already received Bedrocan pre-orders until July 2023, but unfortunately the product is sold out until then. Unfortunately, there are also certain medications that are not permanently available, which can lead to a discontinuation of therapy. However, Bedrocan will continue to be supplied by other German wholesalers to ensure that the therapy option remains continuously available for patients.

At Natural Pharma, they are proud to contribute to ensuring that patients receive continuous and reliable care. The goal is to continuously offer new, traceable, and permanently available therapy options for patients. In collaboration with our partner Beacon Medical Germany, a German subsidiary of the Canadian company VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF), Natural Pharma is achieving these goals and ensuring that the highest quality standards are met. Currently, Beacon Medical Germany is registering new medications with the IFA. By early Q3/23, additional EU-GMP products will be introduced to the market to enable further therapy options for patients.

In the future, Natural Pharma will continue to expand its therapy options by gaining additional partners and receiving medications from its partner Beacon Medical. The products from Beacon Medical Germany are exclusively grown and produced indoors at ABcann Medicinals Inc. in Napanee, Ontario, Canada. The products meet the highest quality standards, including GACP and EU-GMP at a single location. Natural Pharma is proud to offer better support to treating physicians, suffering patients, and distributing pharmacies by providing additional therapy options to enable better quality of life and sustained therapy for patients.

Natural Pharma remains committed to understanding the needs of patients. With the introduction of new products and the expansion of therapy options through partnerships such as Beacon Medical, it is on the right track to achieve this goal.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

About VIVO Cannabis

VIVO Cannabis® is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia.
For more information, visit: VIVO Cannabis Inc. and Beacon Medical Germany.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership
NPR-Press
PRESS RELEASE
18. August 2022

High-Terpen levels confirmed in German labs!

(© https://de.123rf.com/profile_parilovv and © mixed with company logo®)
Langenfeld (rhld.) – Germany, 2022-08-18

Today, we will focus our attention on the “entourage effect” and the important role of “terpenes” in cannabis therapy according to existing scientific research.

Short flashback: The “entourage effect” was first described by Dr. Ben-Shabat in 1998 and was explained and expanded upon in particular by Dr. Ethan Russo. Dr. Ethan Russo, M.D., a neurologist who has long studied cannabis active ingredients and their role in the body extensively, published the following study in 2011: “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects” 

Natural Pharma‘s stance on the “entourage effect” is:

Especially in the medical field, “entourage effect” should not be disregarded. Our partner Beacon Medical Germany, a German subsidiary of the Canadian company VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF), focuses on high-quality and full transparency of the imported cannabis products to Germany. In order to achieve full transparency, we offer in addition to our COA, an up-to-date terpene analysis for each batch. This enables the treating physicians and especially the patients to provide a targeted therapy. Proverb: Entourage effect.

Therefore, we would like to share with you our achievement:

Our partner product, Beacon Indica THC 20 – Sensi Star (Batch 1251SI31401) has been measured and confirmed by a German testing laboratory with a terpene concentration of 2.92%.

In Germany, no one except us offers an up-to-date terpene analysis for the available batches. The reason is, in Germany it is not mandatory to provide terpene information. But with exception of THC and CBD according to the German Pharmacopoeia (DAB).

We placed great emphasis with VIVO Cannabis® and Beacon Medical Germany to provide a transparent medical cannabis product, which has allowed us to gain more and more trust from physicians and patients in Germany.

Further medical cannabis products from VIVO’s large portfolio will follow. Which Canadian products these will be, this is a secret of the companies for the time being.

But we can tell you one thing:

We will continue to introduce transparent medical cannabis products.

 

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

 

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

About VIVO Cannabis

VIVO Cannabis® is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia.
For more information, visit: VIVO Cannabis Inc. and Beacon Medical Germany.

Business partner

Become a partner of us and participate proactively with your resources in the supply chain of the German market for medical and recreational cannabis. As partner and company we can offer security, continuity, transparency and trust.


Contact:
business(ät)natpha.com
Internal forwarding: Press “Business” button please
Business
NPR-Press
PRESS RELEASE
9. August 2022

Welcome to Natural Pharma!

(© Natural Pharma Resource GmbH – Logo)
Langenfeld (rhld.) – Germany, 2022-08-09

Welcome to Natural Pharma! The former founding member and CEO of Medical Pharma Resource GmbH, Mr. Engin Ates, has moved on after 4 years in August 2022 to start a new challenge with Natural Pharma. The new pharmaceutical and biotechnology company will start the distribution to German pharmacies in a timely manner.

An exclusive partnership with Beacon Medical Germany GmbH, a German subsidiary of the Canadian VIVO Cannabis Inc., has been re-established.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany. The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.


We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.
For more information, visit: Natural Pharma

About VIVO Cannabis

VIVO Cannabis® is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia.
For more information, visit: VIVO Cannabis Inc. and Beacon Medical Germany.

Business partner

Become a partner of us and participate proactively with your resources in the supply chain of the German market for medical and recreational cannabis. As partner and company we can offer security, continuity, transparency and trust.


Contact:
business(ät)natpha.com
Internal forwarding: Press “Business” button please
Business
NPR-Press